Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aradigm has received US patent for formulations of inhaled liposomal and free ciprofloxacin including its Pulmaquin (Dual Release Ciprofloxacin for Inhalation, DRCFI, ARD-3150), indicated for lung infection treatment.
Subscribe to our email newsletter
According to the company, the patent will provide exclusivity for Pulmaquin until 22 October 2027.
Pulmaquin is a dual release formulation that is a mixture of a liposomal formulation of ciprofloxacin with unencapsulated ciprofloxacin.
Ciprofloxacin is an antibiotic to treat infections of the lung frequently experienced by cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE) patients.
The drug candidate demonstrated superior performance in clinical study that assesses two different formulations of inhaled ciprofloxacin (ARD-3100 – Lipoquin and ARD-3150 – Pulmaquin).
Aradigm intends to take Pulmaquin forward into Phase 3 clinical trials.